Chemistry:Suzetrigine

From HandWiki

Suzetrigine, sold under the brand name Journavx, is an oral medication used for moderate to severe acute pain management in adults.[1][2] It is a small-molecule non-opioid analgesic that works as a selective inhibitor of Nav1.8-dependent pain-signaling pathways in the peripheral nervous system.[3][4] Nav1.8 channels are predominantly present in peripheral nociceptive neurons of the dorsal root ganglia.[4][5] Suzetrigine inhibits pain signals before they reach the central nervous system and has no addictive potential.[3][6]

The most common adverse reactions include itching, muscle spasms, increased blood level of creatine phosphokinase, and rash.[1][2]

Suzetrigine was developed by Vertex Pharmaceuticals.[7] It was approved for medical use in the United States on January 30, 2025.[2][8] Due to Suzetrigine's novel mechanism of action, it is the first medication to be approved by the US Food and Drug Administration (FDA) in the non-opioid class of medications for the treatment of moderate-to-severe acute pain.[2][5]

Medical uses

Suzetrigine is indicated for the treatment of moderate to severe acute pain in adults.[1][2]

Dosage and administration

Suzetrigine is dispensed as 50 milligram oral tablets that are to be swallowed whole and not crushed or chewed.[1][2] To avoid a delay of onset, it is recommended to begin taking a starting dose of 100 mg on an empty stomach.[6] Following the initial dose, 50 mg is to be taken every 12 hours for the shortest possible duration.[1] For those with moderate hepatic impairment, 50 mg doses are to be taken 24 hours apart following the fifth dose.[1]

Contraindications

Concomitant use of suzetrigine with strong CYP3A4 inhibitors is contraindicated.[1][2] When taken with moderate CYP3A inhibitors, dose adjustments are required.[5] While taking suzetrigine, and for 28 days after use has ended, those taking hormonal contraceptives with progesterone's other than levonorgestrel and norethindrone should use additional or an alternative non-hormonal contraceptive.[8]

Individuals with severe hepatic impairment (Child-Pugh Class C) should not take suzetrigine.[1][8]

Adverse effects

The most common adverse effects of suzetrigine may include itching, rash, muscle spasms, and increased levels of creatine kinase.[2] Mild side effects may include nausea, vomiting, constipation, headache, and dizziness.[9][10] In preliminary research, suzetrigine had no serious neurological, behavioral, addictive or cardiovascular effects.[3]

As of 2024, long-term safety in broader contexts including multimodal analgesia, pregnancy and breastfeeding women remain undetermined.[10]

Interactions

Consuming grapefruit while using suzetrigine may cause adverse grapefruit–drug interactions.[1][2]

Mechanism of action

Suzetrigine operates on Nav1.8 channels predominately found in the peripheral nociceptive neurons of the dorsal root ganglia.[3][4] This mechanism avoids the addictive potential of opioids caused by their effects on the reward system in the central nervous system.[9] Unlike opioid medications, which reduce pain signals in the brain, suzetrigine works by closing sodium channels in peripheral nerves, inhibiting painful sensations from being transmitted to the brain.[3][4][9]

In pharmacological studies, suzetrigine bound to the voltage-sensing domain 2 of Nav1.8 channels with a 3,100-times greater affinity than to other voltage-gated sodium channels.[3][11] Suzetrigine selectively bound to this site on these sodium channels with a novel allosteric mechanism, thereby stabilizing the closed state and causing tonic inhibition.[3]

History

Vertex Pharmaceuticals announced in January 2024 that suzetrigine had successfully met several endpoints in its Phase III clinical trials.[7] The company announced in July 2024 that the FDA had accepted a New Drug Application for suzetrigine.[12] Due to its novel mechanism, the FDA granted priority review, fast track, and breakthrough therapy designations to the application for suzetrigine.[2][12] In January 2025, the FDA granted approval of Journavx to Vertex Pharmaceuticals, making it the first non-opioid pain medication to be approved by the FDA in two decades.[2][13]

As of November 2025, Phase IV post-marketing clinical trials are underway to assess the effectiveness and safety of Suzetrigine as a part of multimodal therapy for the treatment of acute post-operative pain[14].

The manufacturer engaged in lobbying activity promoting non-opioid pain treatment and supporting the NO PAIN Act (Non-Opioids Prevent Addiction In the Nation Act).[15]

Research

Treatment of acute pain using suzetrigine has not been studied beyond 14 days of use.[1]

Efficacy

In clinical studies conducted through 2024, suzetrigine reduced pain typically from 7 to 4 on the standard numeric scale used to rate pain.[9][10] The efficacy of suzetrigine was evaluated in two randomized, double-blind, placebo- and active-controlled trials of acute surgical pain, one following abdominoplasty and the other following bunionectomy.[2] Both trials found that suzetrigine reduced pain more effectively than placebo.[2]

However, in clinical studies, no superiority over hydrocodone and paracetamol (acetaminophen) in terms of pain reduction was shown over 48 hours.[16] Medical professionals have noted its efficacy may be inferior to high-dose opioid analgesics.[17] There are no studies comparing suzetrigine with high-dose opioids. Suzetrigine exhibits CYP3A4-mediated drug interactions and there is limited long-term data regarding its use.[11] Moreover, usage has not been studied in those younger than 18 or older than 80 years of age and its cost-effectiveness is disputed.[7][18]

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 Cite error: Invalid <ref> tag; no text was provided for refs named Journavx FDA label
  2. ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 "FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain" (Press release). U.S. Food and Drug Administration (FDA). 30 January 2025. Archived from the original on 7 February 2025. Retrieved 30 January 2025. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Osteen, Jeremiah D.; Immani, Swapna; Tapley, Tim L.; Indersmitten, Tim; Hurst, Nicole W.; Healey, Tiffany; Aertgeerts, Kathleen; Negulescu, Paul A. et al. (January 2025). "Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain". Pain and Therapy 14 (2): 655–674. doi:10.1007/s40122-024-00697-0. PMID 39775738. 
  4. ↑ 4.0 4.1 4.2 4.3 Jones, Jim; Correll, Darin J.; Lechner, Sandra M; Jazic, Ina; Miao, Xiaopeng; Shaw, David; Simard, Christopher; Osteen, Jeremiah D. et al. (August 2023). "Selective Inhibition of NaV1.8 with VX-548 for Acute Pain". The New England Journal of Medicine 389 (5): 393–405. doi:10.1056/NEJMoa2209870. PMID 37530822. 
  5. ↑ 5.0 5.1 5.2 Wu, Zhixing; Lu, Dai (2026-01-15). "Advances in the discovery of selective NaV1.8 inhibitors for pain management". European Journal of Medicinal Chemistry 302 (Pt 2). doi:10.1016/j.ejmech.2025.118326. ISSN 0223-5234. PMID 41175507. https://www.sciencedirect.com/science/article/pii/S0223523425010918. 
  6. ↑ 6.0 6.1 "Suzetrigine" (in en). https://go.drugbank.com/drugs/DB18927. 
  7. ↑ 7.0 7.1 7.2 "Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain" (Press release). Vertex. 30 January 2024. Archived from the original on 25 December 2024. Retrieved 31 January 2025 – via Business Wire.
  8. ↑ 8.0 8.1 8.2 "Novel Drug Approvals for 2025". 21 February 2025. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025. 
  9. ↑ 9.0 9.1 9.2 9.3 Broadfoot, Marla (20 August 2024). "New Painkiller Could Bring Relief to Millions — without Addiction Risk". Scientific American. https://www.scientificamerican.com/article/new-pain-medication-suzetrigine-prevents-pain-signals-from-reaching-brain/. Retrieved 31 January 2025. 
  10. ↑ 10.0 10.1 10.2 Hang Kong, Aaron Yik; Tan, Hon Sen; Habib, Ashraf S. (September 2024). "VX-548 in the Treatment of Acute Pain". Pain Management 14 (9): 477–486. doi:10.1080/17581869.2024.2421749. PMID 39552600. 
  11. ↑ 11.0 11.1 Jones, Meaghan; Demery, Aryanna; Al-Horani, Rami A. (4 July 2025). "Suzetrigine: A Novel Non-Opioid Analgesic for Acute Pain Management—A Review" (in en). Drugs and Drug Candidates 4 (3): 32. doi:10.3390/ddc4030032. ISSN 2813-2998. PMID 40799996. 
  12. ↑ 12.0 12.1 "Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain" (Press release). Vertex. 30 July 2024. Retrieved 31 January 2025 – via Business Wire.
  13. ↑ Dolgin, Elie (January 2025). "US drug agency approves potent painkiller - the first non-opioid in decades". Nature 638 (8050): 304–305. doi:10.1038/d41586-025-00274-1. PMID 39885357. Bibcode: 2025Natur.638..304D. 
  14. ↑ Vertex Pharmaceuticals Incorporated (2025-11-07). A Phase 4, Open-label, Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine As Part of Multimodal Therapy for Acute Pain After Aesthetic or Reconstructive Surgeries (Report). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06887972. 
  15. ↑ "Lobbying Update: $1,140,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed". 16 July 2025. https://www.nasdaq.com/articles/lobbying-update-1140000-vertex-pharmaceuticals-incorporated-lobbying-was-just-disclosed. 
  16. ↑ Bertoch, Todd; D'Aunno, Dominick; McCoun, Jessica; Solanki, Daneshvari; Taber, Louise; Urban, Joshua; Oswald, Jessica; Swisher, Matthew W. et al. (21 March 2025). "Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials" (in en). Anesthesiology 142 (6): 1085–1099. doi:10.1097/ALN.0000000000005460. ISSN 0003-3022. PMID 40117446. 
  17. ↑ Robinson, Christopher L.; Schatman, Michael E.; Hasoon, Jamal; Chung, Matthew; Emerick, Trent; Lo Bianco, Giuliano; Ashina, Sait; Yong, R. Jason (2025). "Suzetrigine: Is This What We Have Been Waiting for or Just the Beginning?". Journal of Pain Research 18: 2047–2049. doi:10.2147/JPR.S527710. ISSN 1178-7090. PMID 40255364. 
  18. ↑ "Suzetrigine for Acute Pain; Final Report". Institute for Clinical and Economic Review. 31 March 2025. https://icer.org/assessment/acute-pain-2025/. 

Further reading



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Suzetrigine&oldid=4243529"